Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed cutaneous leishmaniasis (untreated) with localized lesions ( without maximum 6 injuries ) and Direct Examination positive : amastigotes display in tissue samples ;~* Age: 16-64 years;~* Sex: male and female patients to eligible ;~* Disease Clinical Evolution not longer than 3 months .~Exclusion Criteria:~* AST \> 3 times the upper limit of normal;~* ALT \> 3 times the upper limit of normal;~* Alkaline phosphatase \> 3 times the upper limit of normal;~* Serum creatinine and urea \> 1.5 times the upper limit of normality;~* Blood glucose above 110 mg / dl;~* Evidence of serious underlying disease ( heart , kidney , liver or lung);~* protein and / or caloric severe malnutrition;~* Any uncompensated or uncontrolled condition like active tuberculosis, malignant disease , severe malaria , HIV, leprosy , systemic fungal disease (histoplasmosis, paracoccidioidomycosis) or any other infectious disease;~* Pregnant women or who are breastfeeding;~* Lack of ability or willingness to provide informed consent (patient and / or parent / legal representative); lack of availability for the visits or to comply with study procedures.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Single dose of Pentamidine (Type: EXPERIMENTAL): Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
- Two doses of Pentamidine (Type: EXPERIMENTAL): Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
- Three doses of Pentamidine (Type: EXPERIMENTAL): Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).